NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) — NetworkNewsAudio, via NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the online availability of its interview with Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP), an emerging pharmaceutical and IP development company who, through its 80 percent owned subsidiary Cannevert Therapeutics Ltd., is advancing the science behind medical cannabis.
The interview can be heard at https://www.networknewswire.com/networknewsaudio/veritas-pharma-inc-cse-vrt-otc-vrthf-interview/
NNW’s Stuart Smith shares a lively discussion with Veritas Pharma CEO Dr. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry. Veritas Pharma’s focus is on medicinal marijuana and the alternative medical applications and therapies the cannabis plant can provide to patients.
“We have the ability to discover drugs and that in itself makes us very distinct, compared to the rest of the landscape,” Franciosi says in praising the scientists, physicians, and other industry specialists on Veritas Pharma’s team. “So, there is a track record of discovery. The actual strains (of cannabis) that we’ve been looking at, the idea is to chemically profile these so that there’s a unique fingerprint.”
Once a specific cannabis strain is scientifically identified, the goal is to be able to reproduce that exact strain repeatedly so that doctors and patients can expect the same therapeutic effect over and over again at least 80 percent of the time, Franciosi explains.
“That standardization is what a lot of physicians want. We’re trying to guarantee, give some sort of warranty, that there will be a regular effect when you take this medication,” he says, adding the company’s research arm – Cannevert Therapeutics Ltd. – received a provisional patent application from the U.S. Patent and Trademark Office for using specific cannabis strains for neuropathic pain.
“Neuropathic pain is a debilitating pain…it’s ongoing,” Franciosi says. “This is one of our first patent applications that we’ve submitted targeting neuropathic pain.”
Veritas Pharma already holds a Health Canada exemption to conduct scientific research with cannabis sourced from one or two legal suppliers in the country. Franciosi said the company is getting closer to receiving a dealer production license, which would allow Veritas Pharma to import and export different varieties of cannabis from around the world. Additionally, the company is now able to become a commercial lab that provides chemical and biological tests for cannabis samples in the Canadian marketplace. The company is also seeking a license to grow and sell specifically cultivated strains of marijuana for medicinal purposes.
“I think that’s the excitement that’s coming; that we will eventually have branded medicine with the Veritas logo saying it’s been scientifically tested. I think that will be the highlight of 2018,” Franciosi said in conclusion.
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 80 percent owned subsidiary Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists and chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multibillion dollar global markets. For more information, visit the company’s website at www.VeritasPharmaInc.com.
NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a complimentary service of NetworkNewsWire. For more information, visit: https://www.networknewswire.com/networknewsaudio/.
NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today’s markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.